Fournier Gangrene, Gas Gangrene, Necrotizing Fasciitis, Necrotizing Soft Tissue Infection
Conditions
Keywords
Fasciitis, Gangrene, Fasciitis, Necrotizing, Soft Tissue Infections, Fournier's Gangrene, Streptococcal septic shock syndrome, Flesh eating bacteria, Meleneys ulcer, Wounds and Injuries, Streptococcus pyogenes, Staphylococcus aureus, Immunopathogenesis, Soft Tissue Infections/blood, Necrosis/blood, Necrosis/diagnosis, Necrosis/mortality, Necrosis/surgery, Prognosis, Risk Factors, Bacterial Infections, Infection, Skin Diseases, Bacterial, Observational study, Biological markers
Brief summary
The purpose of this study is to investigate the immune response in patients with necrotizing soft tissue infections (NSTI). The investigation will focus on inflammatory and vasoactive biomarkers as prognostic markers of severity and mortality at admission to Rigshospitalet and the following 3 days
Detailed description
Necrotizing soft tissue infection (NSTI) is a complex, multi-factorial disease with diverse microbiological etiology and varying co-morbidities. The rapidly spreading infection may cause extensive soft tissue damage, limb loss, and multiple organ failure. The incidence of NSTIs has increased over the past years and the fatality rates are still high despite increased focus on these patients (20-30%). The extensive inflammatory response is thought to be a main course of death. However, it is unknown which biomarkers that are responsible for the deleterious effects and how these molecular mediators are modulated during the infection and treatment regimes. Thus, there is a need for novel insight into the immune system disturbances in order to improve outcome of NSTIs. Location: Copenhagen University Hospital, Rigshospitalet, Denmark. Design: Observational cohort study. Cohort: NSTI patients in Denmark. Controls: 50-100 Patients undergoing elective, orthopedic surgery at Rigshospitalet. Biomarkers: The investigators will focus on three major groups of biomarkers: Acute-phase proteins, cytokines and vasoactive biomarkers. Sample size calculations: 1. Acute-phase proteins: The investigators expect a mean PTX3-concentration at admission at 120 nmol/L in patients without septic shock and a mean PTX3-concentration at 210 nmol/L in patients with septic shock. With an estimated standard deviation at 100 nmol/L, the inclusion of 52 patients will be able to detect a significant difference with a statistical power of 90% at a 5% significance level. Since the groups are unequal the investigators will need to include 82 patients (N'=52(1+4)\^2/4\*4). 2. Cytokines: In a pilot study with seven NSTI patients, the investigators found a minimal clinically relevant difference in IL-6 concentration in NSTI patients with LRINEC \< 6 and ≥ 6 to be 1050 pg/ml. With an estimated standard deviation at 2000 pg/ml, the inclusion of 114 patients will be able to detect a significant difference with a statistical power of 80% at a 5% significance level. 3. Vasoactive proteins: The investigators expect a mean NOx-concentration at admission at 90 μmol/L in patients without septic shock and a mean NOx-concentration at 145 μmol/Lin patients with septic shock. With an estimated standard deviation at 70 μmol/L, the inclusion of 70 patients will be able to detect a significant difference with a statistical power of 90% at a 5% significance level. Since the groups are unequal the investigators will need to include 110 patients (N'=70(1+4)\^2/4\*4). Data: Data will be handled according to the National Data Protection Agency. All original records (incl. consent forms and questionnaires) will be archived at trial site for 15 years. The National Data Protection Agency has approved the biobank (2007-58-0015, J. nr. 30-1282). Ethics: The trial will adhere to the Helsinki Declaration and Danish law. The National Ethics Committee and the Regional Ethics Committee have approved the inclusion of the NSTI patients (CVK-1211709) and the control patients, including biomarker analyses (H-2-2014-071). Biomarker analyses, data extraction and interpretation will be performed once the recruiting of participants has ended.
Interventions
None listed
Sponsors
Seventh Framework Programme
Ole Hyldegaard
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
for patients with NSTI: * Necrotizing soft tissue infection based on surgical findings * Age \>18 years * Admitted to/planned to be admitted to the ICU at Rigshospitalet and/or operated for NSTI at Rigshospitalet
Exclusion criteria
for patients with NSTI: * Patients who at the operating theatre were categorized as non-NSTI patients Inclusion Criteria for control patients: * Patients undergoing elective orthopedic surgery (non-pathologic fractures, joint replacement surgery, back surgery) at Rigshospitalet * Age \>18 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PTX3, NOx and IL-6 as early markers of disease severity in NSTI patients with and without septic shock | Admission, first 24 hours | Primary analysis: Association between PTX3-, NOx-, and IL6-concentration and septic shock (PTX3, NOx) or LRINEC ≥ 6 (IL-6) in NSTI patients at time of admission to Rigshospitalet |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Amputation rate | During ICU admission (expected average of 8 days) | At any anatomical site |
| ICU-scoring systems | During ICU admission (expected average of 8 days) | SAPS II (day 1) APACHE II (day 1) SOFA, GCS excluded (day 1-7), Anaya-score |
| Multiple organ failure | During ICU admission (expected average of 8 days) | — |
| Number of debridements | During ICU admission (expected average of 8 days) | — |
| Microbial etiology | During ICU admission (expected average of 8 days) | Tissue and blood samples |
| Time from admission to primary hospital until first surgery/debridement | 2 days | — |
| Mortality | 28, 90, 180 days | — |
| Steroid treatment (injection/oral intake) up to development of NSTI | Up to 7 days before surgical diagnose at primary hospital | — |
| Inflammatory biomarkers | Admission and the following 3 days | Secondary analysis: The association between inflammatory biomarkers such as CRP, procalcitonin, mannose-binding-lectin and ficolin-1,2,3, cytokines and septic shock, LRINEC ≥ 6 and SAPS II at admission and the following 3 days |
| Vasoactive biomarkers | Admission and the following 3 days | Secondary analysis: The association between vasoactive biomarkers such as NOx (nitrite, NO2-, and nitrate, NO3-,), L-arginine, asymmetric dimethylarginine, hydrogen sulfide, reactive oxygen species, ICAM-1, E-selectin and septic shock, LRINEC ≥ 6 and SAPS II at admission and the following 3 days |
| The effects of immunoglobulin on inflammatory biomarkers | Admission and the following 3 days | A subgroup analysis will be performed on patients randomized to immunoglobulin or saline as immunoglobulin might affect the biomarker response (PTX3, NO, IL-6). The randomized double-blinded study was initiated April 2014 and registered at ClinicalTrials.gov (NCT02111161). |
| Biomarkers and Severity of disease | Admission and the following 3 days | Subgroup analysis: Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock will be diagnosed according to standardized criteria (American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee) and the biomarkers will be investigated to see if there is a correlation between disease severity and mortality in these groups. |
| Ventilator treatment, renal replacement therapy, vasopressor treatment during stay at ICU | During ICU admission (expected average of 8 days) | — |
Countries
Denmark
Outcome results
None listed